Skip to main content
SpringerLink
Log in

Prostate cancer

Impact of national guidelines on brachytherapy monotherapy

  • News & Views
  • Published:

From Nature Reviews Urology

View current issue Sign up to alerts

New research shows that high-risk and intermediate-risk prostate cancers are being treated with brachytherapy alone, deviating from both guidelines and expert opinion. These findings should force intense introspection and scrutiny amongst clinicians, and encourage them to consider whether they are practicing evidence-based medicine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Tseng, Y. D. et al. Impact of national guidelines on brachytherapy monotherapy practice patterns for prostate cancer. Cancer http://dx.doi.org/10.1002/cncr.28492.

  2. Frank, S. J. et al. Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: a survey of practice patterns in the United States. Brachytherapy 6, 2–8 (2007).

    Article  Google Scholar 

  3. Roach, M. 3rd & Thomas, K. Overview of randomized controlled treatment trials for clinically localized prostate cancer: implications for active surveillance and the United States preventative task force report on screening? J. Natl Cancer Inst. Monogr. 2012, 221–229 (2012).

    Article  Google Scholar 

  4. Kimura, M. et al. Current salvage methods for recurrent prostate cancer after failure of primary radiotherapy. BJU Int. 105, 191–201 (2010).

    Article  CAS  Google Scholar 

  5. Mitchell, J. M. Urologists' use of intensity-modulated radiation therapy for prostate cancer. N. Engl. J. Med. 369, 1629–1637 (2013).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, 1600 Divisadero Street, Suite H1031, San Francisco, 94143-1708, CA, USA

    Julian Johnson & Mack Roach III

Authors
  1. Julian Johnson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mack Roach III
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mack Roach III.

Ethics declarations

Competing interests

M.R. has acted as a consultant for Ferring Pharma, Millineum, and ARISTA, and received honoraria from Varian, Prostate Cancer Research Institute, Society of Uro-Oncology (Turkey), Nihon Medi-Physics, Astra-Zeneca, Astellas Pharma, e-HIMS Global Congress on Prostate Cancer, and the ESI Educational Symposium. J.J. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Johnson, J., Roach, M. Impact of national guidelines on brachytherapy monotherapy. Nat Rev Urol 11, 195–196 (2014). https://doi.org/10.1038/nrurol.2014.50

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2014.50

  • Springer Nature Limited

Search

Navigation